You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 14, 2024

DENAVIR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Denavir patents expire, and when can generic versions of Denavir launch?

Denavir is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in DENAVIR is penciclovir. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the penciclovir profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Denavir

A generic version of DENAVIR was approved as penciclovir by TEVA PHARMS USA on November 9th, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DENAVIR?
  • What are the global sales for DENAVIR?
  • What is Average Wholesale Price for DENAVIR?
Summary for DENAVIR
Drug patent expirations by year for DENAVIR
Drug Prices for DENAVIR

See drug prices for DENAVIR

Recent Clinical Trials for DENAVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Squarex, LLCPhase 2

See all DENAVIR clinical trials

Pharmacology for DENAVIR

US Patents and Regulatory Information for DENAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DENAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 ⤷  Sign Up ⤷  Sign Up
Mylan DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 ⤷  Sign Up ⤷  Sign Up
Mylan DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 ⤷  Sign Up ⤷  Sign Up
Mylan DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for DENAVIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0296560 98C0015 Belgium ⤷  Sign Up PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: NL 21 303 19980415; FIRST REGISTRATION: GB - 10592/0078 19960228
0141927 97C0033 Belgium ⤷  Sign Up PRODUCT NAME: PENCICLOVIR; NAT. REGISTRATION NO/DATE: 981 IS 110 F 7; 19970206; FIRST REGISTRATION: GB 10592/0078 19960228
0182024 SPC/GB94/002 United Kingdom ⤷  Sign Up SPC/GB94/002: 20050910, EXPIRES: 20081209
0141927 SPC/GB96/014 United Kingdom ⤷  Sign Up SPC/GB96/014: 20040810, EXPIRES: 20090809
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.